Wound-healing potential of human umbilical cord blood–derived mesenchymal stromal cells in vitro—a pilot study

You, Hi-Jin; Namgoong, Sik; Han, Seung Kyu; Jeong, Seong Ho; Dhong, Eun Sang; Kim, Woo Kyung

doi:10.1016/j.jcyt.2015.06.011

Cited by 28 publications

(16 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs have been widely used due to their substantial multilineage differentiation and immunoregulating activities, in many fields ranging from autoimmune diseases, nervous system diseases, and orthopedic system diseases [ 18 – 21 ]. Many researchers have proved the satisfactory efficacy of MSCI in refractory AID patients.…”

Section: Discussionmentioning

confidence: 99%

Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study

et al. 2018

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to evaluate the safety of mesenchymal stem cell infusion in patients with autoimmune diseases.MethodsA total of 404 patients with autoimmune diseases who received mesenchymal stem cell infusion between 2007 and 2016 were included in this study. Adverse events in these patients were collected, mainly including infections and malignancies. Sources of information included hospitalization records and data from outpatient visits and each follow-up.ResultsThe mean follow-up period of all patients was 43.4 ± 25.9 months (range 1–109). Majority of stem cells were from the umbilical cord. The most common indications for mesenchymal stem cell infusion were systemic lupus erythematosus, Sjögren’s syndrome, and systemic sclerosis. The median age at infusion was 38.7 ± 15.7 years. The 5-year and 8-year survival rates were 90.4% and 88.9%, respectively. Median follow-up of survivors was 45.1 ± 25.7 months. The incidence rate of infections was 29.5% (119/404), and that of serious infections was 12.9% (52/404). Five patients (1.2%) experienced malignancies. Deaths occurred in 45 patients, and transplantation-related mortality was 0.2%. The most common causes of deaths in our study were disease relapse and complications associated with the underlying disease.ConclusionAutoimmune disease is an emerging indication for mesenchymal stem cell infusion. Our data shows that mesenchymal stem cell infusion is a safe therapy for patients with autoimmune diseases. The incidences of adverse events, whether infections or malignancies, are acceptable in these patients.Trial registrationClinaicalTrials.gov, NCT00698191. Registered 17 June 2008—Retrospectively registered

show abstract

Section: Discussionmentioning

confidence: 99%

Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Additionally, the activity of diabetic fibroblasts cultured with hUCB‐MSCs was greater than that with healthy fibroblasts. The previous in vitro study by the authors demonstrated that hUCB‐MSCs are superior to fibroblasts in the production of major growth factors associated with wound healing but are not in collagen synthesis . Consequently, the results of the present study show that although hUCB‐MSCs do not secrete much more extracellular matrix components by themselves than fibroblasts, treatment with hUCB‐MSCs stimulates extracellular matrix synthesis, including collagen, of diabetic fibroblasts much greater than that with fibroblasts.…”

Section: Discussionmentioning

confidence: 99%

Comparison of human umbilical cord blood‐derived mesenchymal stem cells with healthy fibroblasts on wound‐healing activity of diabetic fibroblasts

Jung

Yoon

Lee

et al. 2017

International Wound Journal

Self Cite

View full text Add to dashboard Cite

of human umbilical cord blood-derived mesenchymal stem cells with healthy fibroblasts on wound-healing activity of diabetic fibroblasts. Int Wound J 2018; 15:133-139 AbstractVarious types of skin substitutes composed of fibroblasts and/or keratinocytes have been used for the treatment of diabetic ulcers. However, the effects have generally not been very dramatic. Recently, human umbilical cord blood-derived mesenchymal stromal cells (hUCB-MSCs) have been commercialised for cartilage repair as a first cell therapy product using allogeneic stem cells. In a previous pilot study, we reported that hUCB-MSCs have a superior wound-healing capability compared with fibroblasts. The present study was designed to compare the treatment effect of hUCB-MSCs with that of fibroblasts on the diabetic wound healing in vitro. Diabetic fibroblasts were cocultured with healthy fibroblasts or hUCB-MSCs. Five groups were evaluated: group I, diabetic fibroblasts without coculture; groups II and III, diabetic fibroblasts cocultured with healthy fibroblasts or hUCB-MSCs; and groups IV and V, no cell cocultured with healthy fibroblasts or hUCB-MSCs. After a 3-day incubation, cell proliferation, collagen synthesis levels and glycosaminoglycan levels, which are the major contributing factors in wound healing, were measured. As a result, a hUCB-MSC-treated group showed higher cell proliferation, collagen synthesis and glycosaminoglycan level than a fibroblast-treated group. In particular, there were significant statistical differences in collagen synthesis and glycosaminoglycan levels (P = 0⋅029 and P = 0⋅019, respectively). In conclusion, these results demonstrate that hUCB-MSCs may have a superior effect to fibroblasts in stimulating diabetic wound healing.

show abstract

“…In vitro, human UCB-MSCs might have capacity for diabetic wound healing by producing VEGF and basic fibroblast growth factor (bFGF) [71]. …”

Section: Umbilical Cord Blood-derived Mesenchymal Stem Cells (Ucb-mentioning

confidence: 99%

Mesenchymal Stem Cells Improve Healing of Diabetic Foot Ulcer

Cao

Gang

Wang

2017

Journal of Diabetes Research

137

119

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs), an ideal cell source for regenerative therapy with no ethical issues, play an important role in diabetic foot ulcer (DFU). Growing evidence has demonstrated that MSCs transplantation can accelerate wound closure, ameliorate clinical parameters, and avoid amputation. In this review, we clarify the mechanism of preclinical studies, as well as safety and efficacy of clinical trials in the treatment of DFU. Bone marrow-derived mesenchymal stem cells (BM-MSCs), compared with MSCs derived from other tissues, may be a suitable cell type that can provide easy, effective, and cost-efficient transplantation to treat DFU and protect patients from amputation.

show abstract

Wound-healing potential of human umbilical cord blood–derived mesenchymal stromal cells in vitro—a pilot study

Cited by 28 publications

References 32 publications

Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study

Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study

Comparison of human umbilical cord blood‐derived mesenchymal stem cells with healthy fibroblasts on wound‐healing activity of diabetic fibroblasts

Mesenchymal Stem Cells Improve Healing of Diabetic Foot Ulcer

Contact Info

Product

Resources

About